Sanofi SA
Health Care
Current price
Target price 00%
Ranks rating
76
Position in sub-industry
374 / 1328
Position in country
295 / 834
Net income margin, %
7.9
2.8
EBITDA margin, %
33.5
10.8
Debt to Equity, %
24.8
19.2
Intangible assets and goodwill, %
58.2
3.6
Revenue CAGR 3Y, %
7.5
8.5
Revenue Y, % chg
5.9
0.5
P/E
20
22.7
P/BV
1.4
1.5
P/S
2.3
2.3
EV/S
2.5
2.4
EV/EBITDA
7.9
7.4
Average Analyst recommendation
Buy
Buy
Average upside forecasts, %
26.5
51.3
Forward P/E
10.6
15.6
Dividend Yield, %
4.3
1.7
Forward Dividend Yield, %
4.5
0.2
Expected dividend per share
2
0
Payout Ratio, %
163.9
30.3
Dividend Ex Date
2024-05-09
Competitors
Ranks
-
Ipsen SA
00%
-
Novo Nordisk A/S
00%
-
Sanofi SA
00%
-
AstraZeneca PLC
00%
-
Vetoquinol SA
00%
-
Eli Lilly and Co
00%
-
Virbac SA
00%
-
Novartis AG
00%
-
Johnson & Johnson
00%
-
Merck & Co Inc
00%
Ready-made portfolio of the best Russian stocks
- Created by artificial intelligence
- Verified by analysts
- Available even to beginners
Company information
Country
France
Sector
Health Care
Industry group
Pharmaceuticals, Biotechnology & Life Sciences
Industry
Pharmaceuticals
Sub-sector
Health Care
Capitalization (millions of $)
117293.4
Ticker
SNY.OQ
ISIN
US80105N1054
IPO date
2002-07-01
Availability on Russian exchanges
Yes
Reporting for
2024-02-23
Date fact. publication of reports
2023-12-31
Company Description
Sanofi SA is a healthcare company based in France. The Company focuses on patient needs and engages in the research, development, manufacture, and marketing of therapeutic solutions. Its three operating segments are: Pharmaceuticals, Consumer Healthcare (CHC), and Vaccines. The Pharmaceuticals includes: Immunology, Multiple Sclerosis / Neurology, Oncology, Rare Diseases, Rare Blood Disorders, Cardiovascular, Diabetes, Established Prescription Products. The Vaccines segment comprises, for all geographical territories, the commercial operations of Sanofi Pasteur, together with research, development, and production activities dedicated to vaccines. The CHC segment comprises the commercial operations for Sanofi’s Consumer Healthcare products, together with research, development and production activities dedicated to those products. The Company’s products developed in collaboration or franchise include Dupixent, Aubagio, Lemtrada, Cerezyme, Lumizyme, Jevtana, Fabrazyme, among others.
A step towards better analytics
- find the best promotions through the Screener
- keep an eye on stock valuation
- download detailed reports
and much more after free registration
RegistrationMore convenient from your phone? Download: